Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Esperion Therapeutics reports robust Q4 earnings, eyes global expansion

Esperion Therapeutics delivered strong financial results in Q4 2022, driven by successful formulary additions and international partner growth.
The company faces challenges in increasing brand awareness and effectively positioning bempedoic acid post statins, requiring strategic marketing and market access initiatives.
Opportunities lie in leveraging upcoming trial results for label expansion, enhancing brand visibility, and capitalizing on international growth through partnerships.

Esperion Therapeutics excels in Q1 2023, poised for market opportunities

Esperion Therapeutics delivered robust Q1 results with revenue growth and positive market reactions to its studies. While facing legal challenges and operational discussions, the company is well-positioned to leverage opportunities in the market through its strong partnerships and financial stability.

Esperion Therapeutics excels in Q2 earnings, eyes label expansion opportunities

Esperion Therapeutics delivered strong financial performance in Q2 2023, driven by revenue growth, cost management, and strategic partnerships.
While facing challenges in managing expenses, the company is well-positioned to capitalize on market opportunities post-label expansion approvals.
With a solid cash position, ongoing operational efficiency efforts, and a focus on growth initiatives, Esperion is poised for continued success.
The company's commitment to innovation and patient outcomes bodes well for its future growth trajectory and market competitiveness.

Esperion Therapeutics excels in Q3 earnings amidst regulatory hurdles

Esperion Therapeutics delivered strong financial results in Q3 2023, driven by revenue growth and strategic collaborations, despite facing regulatory and litigation challenges.
The company's focus on expanding market presence through FDA approvals and international expansion presents promising growth avenues for future success.
With a solid financial position and ongoing initiatives to drive prescription growth, Esperion is poised to capitalize on market opportunities and navigate challenges effectively.

Esperion Therapeutics reports robust Q4 earnings and eyes market expansion

Esperion Therapeutics delivered strong financial performance in Q4 2023, showcasing significant revenue growth and strategic advancements.
While facing challenges in managing expenses and executing growth strategies, the company is well-positioned to capitalize on market opportunities and drive future expansion.
With a clear roadmap for expense management and a focus on product reach and market expansion, Esperion is poised for continued growth and value creation for stakeholders.
The settlement agreement and label expansion approvals provide a solid foundation for Esperion to leverage opportunities, overcome challenges, and drive sustainable growth.

Esperion Therapeutics posts robust Q1 results amid FDA label wins

Esperion Therapeutics delivered strong financial performance in Q1 2024, driven by revenue growth and FDA label expansions.
The company faces challenges in maintaining prescription growth and navigating payer dynamics post-label update.
Strategic initiatives and market opportunities present avenues for Esperion to capitalize on its recent successes and drive future growth.

Esperion Therapeutics reports robust Q2 revenue growth and global expansion

Esperion Therapeutics delivered strong financial performance in Q2 2024, driven by revenue growth and successful market expansion efforts.
While facing challenges such as debt extinguishment losses and high operating expenses, the company capitalized on opportunities for international growth and product marketability.
By leveraging strengths in expanded product labels and improved market access, Esperion is poised to navigate challenges and capitalize on growth opportunities in the pharmaceutical sector.

Esperion Therapeutics reports robust Q3 performance and eyes global expansion

Esperion Therapeutics delivered strong financial performance in Q3 2024, driven by revenue growth and strategic initiatives to expand market access and product offerings.
While challenges in achieving profitability persist, the company's focus on innovation, global expansion, and operational efficiency underscores its long-term growth potential.
By leveraging strengths in collaboration, research, and market differentiation, Esperion is poised to capitalize on opportunities for further international expansion and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Cardiff Oncology

Ubiquiti Inc

Vodafone Group

Advantest Corp

Deere & Company

Fluence Energy

StealthGas

Huntington Ingalls Industries

Himax Tech

Payoneer Global

Ready Capital Corp

Teradyne

TORM

The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational improvements, Ready Capital Corporation faces liquidity risks, and TORM plc is crucial despite energy sector volatility. Esperion Therapeutics' breakout and Cardiff Oncology's promising trial data present compelling buy opportunities, while Advantest Corporation's high valuation suggests caution.

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain holders of its outstanding 4.00% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”). Pursuant to the Agreements, Esperion will issue $100 million aggregate principal amount of its 5.75% Convertible Senior Subordinated Notes due 2030 (the “New Notes”) consisting of (a) approximately $57.5 million principal amount of New Notes, along with approximately $153.4 million in cash, issued in exchange for approximately $210.1 million principal amount of the 2025 Notes (the “Exchange Transactions”) and (b) approximately $42.5 million principal amount of New Notes for cash (the “Subscription Transactions”), in each case, pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities Act”).

Esperion Announces $210 Million Convertible Debt Financing

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years – ANN ARBOR, Mich., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel.

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance.

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence.

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates.

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.37 per share a year ago.

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with  U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth –

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET.

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.

Esperion to Report Third Quarter 2024 Financial Results on November 7

ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives –

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET.

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy rating for Esperion Therapeutics, Inc. based on current execution and expanding international scope.

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough.

Esperion Therapeutics: Strategically Positioned To Grow

Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript

Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates.

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.

News for Esperion Therapeutics Stock (ESPR)